{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:20:26Z","timestamp":1793737226024,"version":"4.6.1"},"reference-count":185,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08602-3","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:24:20Z","timestamp":1783938260000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Spatial organization of the TNBC tumor microenvironment: multicellular niches, T-cell bottlenecks, and therapeutic opportunities"],"prefix":"10.1186","volume":"24","author":[{"given":"Jinpeng","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Sha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"issue":"1","key":"8602_CR1","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1186\/s12967-025-06786-8","volume":"23","author":"VP Nimbalkar","year":"2025","unstructured":"Nimbalkar VP, Snijesh VP, Rajarajan S, Anupama CE, Mahalakshmi S, Alexander A, et al. Spatial profiling reveals unique immune microenvironment in premenopausal triple-negative breast cancer associated with therapy response. J Transl Med. 2025;23(1):761. https:\/\/doi.org\/10.1186\/s12967-025-06786-8.","journal-title":"J Transl Med"},{"key":"8602_CR2","doi-asserted-by":"publisher","unstructured":"O\u2019CONNELL BC, Hubbard C, Zizlsperger N, Fitzgerald D, Kutok JL, Varner J, et al. Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment. J Immunother Cancer. 2024;12(8). https:\/\/doi.org\/10.1136\/jitc-2024-009160.","DOI":"10.1136\/jitc-2024-009160"},{"issue":"11","key":"8602_CR3","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674\u201390. https:\/\/doi.org\/10.1038\/nrclinonc.2016.66.","journal-title":"Nat Rev Clin Oncol"},{"key":"8602_CR4","doi-asserted-by":"publisher","first-page":"1521388","DOI":"10.3389\/fimmu.2025.1521388","volume":"16","author":"Y Xin","year":"2025","unstructured":"Xin Y, Ma Q, Deng Q, Wang T, Wang D, Wang G. Analysis of single-cell and spatial transcriptomics in TNBC cell-cell interactions. Front Immunol. 2025;16:1521388. https:\/\/doi.org\/10.3389\/fimmu.2025.1521388.","journal-title":"Front Immunol"},{"key":"8602_CR5","doi-asserted-by":"publisher","first-page":"1735893","DOI":"10.3389\/fimmu.2025.1735893","volume":"16","author":"R Chai","year":"2025","unstructured":"Chai R, Zhang Z, Gong Z, Li Q, Dong C. Multi-omics profiling unravel the immune landscape diversity by prognostic signatures of immunotherapy response in triple-negative breast cancer. Front Immunol. 2025;16:1735893. https:\/\/doi.org\/10.3389\/fimmu.2025.1735893.","journal-title":"Front Immunol"},{"issue":"2","key":"8602_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer \u2014 expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19(2):91\u2013113. https:\/\/doi.org\/10.1038\/s41571-021-00565-2.","journal-title":"Nat Rev Clin Oncol"},{"key":"8602_CR7","doi-asserted-by":"publisher","first-page":"105111","DOI":"10.1016\/j.critrevonc.2025.105111","volume":"218","author":"Z Yuan","year":"2026","unstructured":"Yuan Z, Liu Z, Zhou M, Wen H, Li B. Research progress on immunotherapeutics for triple-negative breast cancer from a single-cell perspective. Crit Rev Oncol\/Hematol. 2026;218:105111. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105111.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"22","key":"8602_CR8","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1809615.","journal-title":"N Engl J Med"},{"issue":"3","key":"8602_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW, Im S-A, Yusof MM, Gallardo C, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387(3):217\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2202809.","journal-title":"N Engl J Med"},{"key":"8602_CR10","doi-asserted-by":"publisher","first-page":"106836","DOI":"10.1016\/j.compbiomed.2023.106836","volume":"158","author":"K Kang","year":"2023","unstructured":"Kang K, Wu Y, Han C, Wang L, Wang Z, Zhao A. Homologous recombination deficiency in triple-negative breast cancer: multi-scale transcriptomics reveals distinct tumor microenvironments and limitations in predicting immunotherapy response. Comput Biol Med. 2023;158:106836. https:\/\/doi.org\/10.1016\/j.compbiomed.2023.106836.","journal-title":"Comput Biol Med"},{"issue":"1","key":"8602_CR11","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1038\/s41467-023-37806-0","volume":"14","author":"JM Carter","year":"2023","unstructured":"Carter JM, Chumsri S, Hinerfeld DA, Ma Y, Wang X, Zahrieh D, et al. Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer. Nat Commun. 2023;14(1):2215. https:\/\/doi.org\/10.1038\/s41467-023-37806-0.","journal-title":"Nat Commun"},{"issue":"7980","key":"8602_CR12","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41586-023-06498-3","volume":"621","author":"XQ Wang","year":"2023","unstructured":"Wang XQ, Danenberg E, Huang CS, Egle D, Callari M, Bermejo B, et al. Spatial predictors of immunotherapy response in triple-negative breast cancer. Nature. 2023;621(7980):868\u201376. https:\/\/doi.org\/10.1038\/s41586-023-06498-3.","journal-title":"Nature"},{"key":"8602_CR13","doi-asserted-by":"publisher","first-page":"217865","DOI":"10.1016\/j.canlet.2025.217865","volume":"628","author":"H Sabit","year":"2025","unstructured":"Sabit H, Adel A, Abdelfattah MM, Ramadan RM, Nazih M, Abdel-Ghany S, et al. The role of tumor microenvironment and immune cell crosstalk in triple-negative breast cancer (TNBC): emerging therapeutic opportunities. Cancer Lett. 2025;628:217865. https:\/\/doi.org\/10.1016\/j.canlet.2025.217865.","journal-title":"Cancer Lett"},{"issue":"1","key":"8602_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s40164-025-00672-1","volume":"14","author":"Y Tang","year":"2025","unstructured":"Tang Y, Xu A, Xu Z, Xie J, Huang W, Zhang L, et al. Multi-omics analyses of the heterogenous immune microenvironment in triple-negative breast cancer implicate UQCRFS1 potentiates tumor progression. Exp Hematol Oncol. 2025;14(1):85. https:\/\/doi.org\/10.1186\/s40164-025-00672-1.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"8602_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s00018-025-06056-2","volume":"83","author":"Q Ma","year":"2026","unstructured":"Ma Q, Wang J, Jiang Q. CA9+ cancer-associated fibroblasts cooperate with SPP1+ tumor-associated macrophages driving immune resistance in triple-negative breast cancer. Cell Mol Life Sci. 2026;83(1):54. https:\/\/doi.org\/10.1007\/s00018-025-06056-2.","journal-title":"Cell Mol Life Sci"},{"key":"8602_CR16","doi-asserted-by":"publisher","first-page":"1263537","DOI":"10.3389\/fimmu.2023.1263537","volume":"14","author":"P Huang","year":"2023","unstructured":"Huang P, Zhou X, Zheng M, Yu Y, Jin G, Zhang S. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer. Front Immunol. 2023;14:1263537. https:\/\/doi.org\/10.3389\/fimmu.2023.1263537.","journal-title":"Front Immunol"},{"issue":"10","key":"8602_CR17","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1016\/j.cmet.2025.08.009","volume":"37","author":"Y Xiao","year":"2025","unstructured":"Xiao Y, Xu Y, Wang H, Yang F, Ding X-H, Fu T, et al. HEBP2-governed glutamine competition between tumor and macrophages dictates immunotherapy efficacy in triple-negative breast cancer. Cell MetabCell Metab. 2025;37(10):2030\u201347.e7. https:\/\/doi.org\/10.1016\/j.cmet.2025.08.009.","journal-title":"Cell MetabCell Metab"},{"issue":"6","key":"8602_CR18","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.cell.2018.08.039","volume":"174","author":"L Keren","year":"2018","unstructured":"Keren L, Bosse M, Marquez D, Angoshtari R, Jain S, Varma S, et al. A structured tumor-immune microenvironment in triple negative breast cancer revealed by Multiplexed ion beam imaging. Cell. 2018;174(6):1373\u201387.e19. https:\/\/doi.org\/10.1016\/j.cell.2018.08.039.","journal-title":"Cell"},{"issue":"4","key":"8602_CR19","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1172\/JCI96313","volume":"129","author":"T Gruosso","year":"2019","unstructured":"Gruosso T, Gigoux M, Manem VSK, Bertos N, Zuo D, Perlitch I, et al. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. J Clin Investigation. 2019;129(4):1785\u2013800. https:\/\/doi.org\/10.1172\/JCI96313.","journal-title":"J Clin Investigation"},{"issue":"1","key":"8602_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13058-025-02132-4","volume":"27","author":"I Park","year":"2025","unstructured":"Park I, Shin SJ, Go H, Ko J, Bae SJ, Ahn SG, et al. Spatial analysis of tumor immune microenvironment of TNBC with different neoadjuvant chemotherapy outcomes using multiplex immunofluorescence. Breast Cancer Res. 2025;27(1):181. https:\/\/doi.org\/10.1186\/s13058-025-02132-4.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"8602_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13058-023-01760-y","volume":"26","author":"SJ Hachey","year":"2024","unstructured":"Hachey SJ, Hatch CJ, Gaebler D, Mocherla A, Nee K, Kessenbrock K, et al. Targeting tumor\u2013stromal interactions in triple-negative breast cancer using a human vascularized micro-tumor model. Breast Cancer Res. 2024;26(1):5. https:\/\/doi.org\/10.1186\/s13058-023-01760-y.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"8602_CR22","doi-asserted-by":"publisher","first-page":"10232","DOI":"10.1038\/s41467-024-54145-w","volume":"15","author":"X Wang","year":"2024","unstructured":"Wang X, Venet D, Lifrange F, Larsimont D, Rediti M, Stenbeck L, et al. Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications. Nat Commun. 2024;15(1):10232. https:\/\/doi.org\/10.1038\/s41467-024-54145-w.","journal-title":"Nat Commun"},{"issue":"1","key":"8602_CR23","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2023.12.012","volume":"42","author":"SL Shiao","year":"2024","unstructured":"Shiao SL, Gouin KH, Ing N, Ho A, Basho R, Shah A, et al., 3RD, ING N, Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer. Cancer Cell. 2024;42(1):70\u201384.e8. https:\/\/doi.org\/10.1016\/j.ccell.2023.12.012.","journal-title":"Cancer Cell"},{"issue":"1","key":"8602_CR24","doi-asserted-by":"publisher","first-page":"6584","DOI":"10.1038\/s41467-025-61034-3","volume":"16","author":"Q Zhu","year":"2025","unstructured":"Zhu Q, Balasubramanian A, R JR, Chatterjee M, Piyarathna B, Kaur J, et al. Integrative spatial omics reveals distinct tumor-promoting multicellular niches and immunosuppressive mechanisms in black American and White American patients with TNBC. Nat Commun. 2025;16(1):6584. https:\/\/doi.org\/10.1038\/s41467-025-61034-3.","journal-title":"Nat Commun"},{"issue":"11","key":"8602_CR25","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1038\/s41591-024-03215-z","volume":"30","author":"J Klughammer","year":"2024","unstructured":"Klughammer J, L DL, Segerstolpe \u00c5, Blosser TR, Goltsev Y, Cui Y, et al. A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features. Nat Med. 2024;30(11):3236\u201349. https:\/\/doi.org\/10.1038\/s41591-024-03215-z.","journal-title":"Nat Med"},{"issue":"5","key":"8602_CR26","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41588-022-01041-y","volume":"54","author":"E Danenberg","year":"2022","unstructured":"Danenberg E, Bardwell H, T VRT, Provenzano E, Chin S-F, Rueda OM, et al. Breast tumor microenvironment structures are associated with genomic features and clinical outcome. Nat Genet. 2022;54(5):660\u201369. https:\/\/doi.org\/10.1038\/s41588-022-01041-y.","journal-title":"Nat Genet"},{"issue":"2","key":"8602_CR27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s43018-020-0026-6","volume":"1","author":"HR Ali","year":"2020","unstructured":"Ali HR, Jackson HW, T VRT, Danenberg E, Fischer JR, Bardwell H, et al. Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer. Nat Cancer. 2020;1(2):163\u201375. https:\/\/doi.org\/10.1038\/s43018-020-0026-6.","journal-title":"Nat Cancer"},{"issue":"7796","key":"8602_CR28","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41586-019-1876-x","volume":"578","author":"HW Jackson","year":"2020","unstructured":"Jackson HW, R JR, T VRT, Ali HR, Mechera R, Soysal SD, et al. The single-cell pathology landscape of breast cancer. Nature. 2020;578(7796):615\u201320. https:\/\/doi.org\/10.1038\/s41586-019-1876-x.","journal-title":"Nature"},{"issue":"9","key":"8602_CR29","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/s41588-021-00911-1","volume":"53","author":"SZ Wu","year":"2021","unstructured":"Wu SZ, Al-Eryani G, Roden DL, Junankar S, Harvey K, Andersson A, et al. A single-cell and spatially resolved atlas of human breast cancers. Nat Genet. 2021;53(9):1334\u201347. https:\/\/doi.org\/10.1038\/s41588-021-00911-1.","journal-title":"Nat Genet"},{"issue":"5","key":"8602_CR30","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.cell.2018.05.060","volume":"174","author":"E Azizi","year":"2018","unstructured":"Azizi E, Carr AJ, Plitas G, Cornish AE, Konopacki C, Prabhakaran S, et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell. 2018;174(5):1293\u2013308.e36. https:\/\/doi.org\/10.1016\/j.cell.2018.05.060.","journal-title":"Cell"},{"issue":"5","key":"8602_CR31","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.cell.2019.03.005","volume":"177","author":"J Wagner","year":"2019","unstructured":"Wagner J, A MA, Chevrier S, Anzeneder T, Langwieder C, Dykgers A, et al. A single-cell atlas of the tumor and immune ecosystem of human breast cancer. Cell. 2019;177(5):1330\u201345.e18. https:\/\/doi.org\/10.1016\/j.cell.2019.03.005.","journal-title":"Cell"},{"issue":"1","key":"8602_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/0008-5472.CAN-22-2682","volume":"83","author":"R Bassiouni","year":"2023","unstructured":"Bassiouni R, O MO, Gibbs LD, Robila V, Grizzard PJ, Webb MG, et al. Spatial Transcriptomic analysis of a diverse patient cohort reveals a conserved architecture in triple-negative breast cancer. Cancer Res. 2023;83(1):34\u201348. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-2682.","journal-title":"Cancer Res"},{"issue":"1","key":"8602_CR33","doi-asserted-by":"publisher","first-page":"5150","DOI":"10.1038\/s41467-018-07582-3","volume":"9","author":"M Bartoschek","year":"2018","unstructured":"Bartoschek M, Oskolkov N, Bocci M, L\u00f6vrot J, Larsson C, Sommarin M, et al. Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Nat Commun. 2018;9(1):5150. https:\/\/doi.org\/10.1038\/s41467-018-07582-3.","journal-title":"Nat Commun"},{"issue":"7934","key":"8602_CR34","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41586-022-05272-1","volume":"611","author":"AT T","year":"2022","unstructured":"T AT, Shyer JA, Thai M, Gandham V, Buechler MB, Yang YA, et al. LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity. Nature. 2022;611(7934):148\u201354. https:\/\/doi.org\/10.1038\/s41586-022-05272-1.","journal-title":"Nature"},{"issue":"12","key":"8602_CR35","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1016\/j.immuni.2023.11.002","volume":"56","author":"T Taifour","year":"2023","unstructured":"Taifour T, Attalla SS, Zuo D, Gu Y, Sanguin-Gendreau V, Proud H, et al. The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer. Immunity. 2023;56(12):2755\u201372.e8. https:\/\/doi.org\/10.1016\/j.immuni.2023.11.002.","journal-title":"Immunity"},{"issue":"1","key":"8602_CR36","doi-asserted-by":"publisher","first-page":"6579","DOI":"10.1038\/s41467-022-34000-6","volume":"13","author":"D Zimmerli","year":"2022","unstructured":"Zimmerli D, S CS, Talens F, Bhin J, Linstra R, Romanens L, et al. MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling. Nat Commun. 2022;13(1):6579. https:\/\/doi.org\/10.1038\/s41467-022-34000-6.","journal-title":"Nat Commun"},{"issue":"2","key":"8602_CR37","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1158\/2159-8290.CD-23-0519","volume":"14","author":"BC Taylor","year":"2024","unstructured":"Taylor BC, Sun X, I PI, Sanchez V, Sanders ME, Wescott EC, et al. NKG2A is a therapeutic vulnerability in immunotherapy resistant MHC-I heterogeneous triple-negative breast cancer. Cancer DiscovCancer Discov. 2024;14(2):290\u2013307. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0519.","journal-title":"Cancer DiscovCancer Discov"},{"issue":"5","key":"8602_CR38","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1158\/2326-6066.CIR-15-0243","volume":"4","author":"A Forero","year":"2016","unstructured":"Forero A, Li Y, Chen D, Grizzle WE, Updike KL, Merz ND, et al. Expression of the MHC class II pathway in triple-negative breast cancer tumor cells is associated with a Good prognosis and infiltrating lymphocytes. Cancer Immunol Res. 2016;4(5):390\u201399. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0243.","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"8602_CR39","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/s41591-018-0078-7","volume":"24","author":"P Savas","year":"2018","unstructured":"Savas P, Virassamy B, Ye C, Salim A, Mintoff CP, Caramia F, et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat Med. 2018;24(7):986\u201393. https:\/\/doi.org\/10.1038\/s41591-018-0078-7.","journal-title":"Nat Med"},{"key":"8602_CR40","doi-asserted-by":"publisher","unstructured":"Lee YJ, Kim JY, Jeon SH, Nam H, Jung JH, Jeon M, et al. CD39 + tissue-resident memory CD8 + T cells with a clonal overlap across compartments mediate antitumor immunity in breast cancer. Sci Immunol. 2022;7(74):eabn 8390. https:\/\/doi.org\/10.1126\/sciimmunol.abn8390.","DOI":"10.1126\/sciimmunol.abn8390"},{"issue":"3","key":"8602_CR41","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.ccell.2023.01.004","volume":"41","author":"B Virassamy","year":"2023","unstructured":"Virassamy B, Caramia F, Savas P, Sant S, Wang J, Christo SN, et al. Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer. Cancer Cell. 2023;41(3):585\u2013601.e8. https:\/\/doi.org\/10.1016\/j.ccell.2023.01.004.","journal-title":"Cancer Cell"},{"issue":"1","key":"8602_CR42","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41467-022-35238-w","volume":"14","author":"S Tietscher","year":"2023","unstructured":"Tietscher S, Wagner J, Anzeneder T, Langwieder C, Rees M, Sobottka B, et al. A comprehensive single-cell map of T cell exhaustion-associated immune environments in human breast cancer. Nat Commun. 2023;14(1):98. https:\/\/doi.org\/10.1038\/s41467-022-35238-w.","journal-title":"Nat Commun"},{"issue":"3","key":"8602_CR43","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","volume":"33","author":"A Costa","year":"2018","unstructured":"Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell. 2018;33(3):463\u201379.e10. https:\/\/doi.org\/10.1016\/j.ccell.2018.01.011.","journal-title":"Cancer Cell"},{"issue":"4","key":"8602_CR44","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","volume":"22","author":"M Philip","year":"2022","unstructured":"Philip M, Schietinger A. CD8+ T cell differentiation and dysfunction in cancer. Nat Rev Immunol. 2022;22(4):209\u201323. https:\/\/doi.org\/10.1038\/s41577-021-00574-3.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"8602_CR45","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","volume":"50","author":"I Siddiqui","year":"2019","unstructured":"Siddiqui I, Schaeuble K, Chennupati V, Fuertes Marraco SA, Calderon-Copete S, Pais Ferreira D, et al. Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like Properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity. 2019;50(1):195\u2013211.e10. https:\/\/doi.org\/10.1016\/j.immuni.2018.12.021.","journal-title":"Immunity"},{"issue":"2","key":"8602_CR46","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41577-019-0223-7","volume":"20","author":"A Kallies","year":"2020","unstructured":"Kallies A, Zehn D, T DT. Precursor exhausted T cells: key to successful immunotherapy? Nat Rev Immunol. 2020;20(2):128\u201336. https:\/\/doi.org\/10.1038\/s41577-019-0223-7.","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"8602_CR47","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/s41590-018-0145-8","volume":"19","author":"P Michea","year":"2018","unstructured":"Michea P, Noel F, Zakine E, Czerwinska U, Sirven P, Abouzid O, et al. Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific. Nat Immunol. 2018;19(8):885\u201397. https:\/\/doi.org\/10.1038\/s41590-018-0145-8.","journal-title":"Nat Immunol"},{"issue":"5","key":"8602_CR48","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","volume":"172","author":"JP B\u00f6ttcher","year":"2018","unstructured":"B\u00f6ttcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, et al. NK cells Stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell. 2018;172(5):1022\u201337.e14. https:\/\/doi.org\/10.1016\/j.cell.2018.01.004.","journal-title":"Cell"},{"issue":"7822","key":"8602_CR49","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41586-020-2611-3","volume":"584","author":"ST Ferris","year":"2020","unstructured":"Ferris ST, Durai V, Wu R, Theisen DJ, Ward JP, Bern MD, et al. cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity. Nature. 2020;584(7822):624\u201329. https:\/\/doi.org\/10.1038\/s41586-020-2611-3.","journal-title":"Nature"},{"key":"8602_CR50","doi-asserted-by":"publisher","unstructured":"Lei X, Khatri I, Wit T, I, Nieuwland M, Kerkhoven R, et al. CD4+ helper T cells endow cDC1 with cancer-impeding functions in the human tumor micro-environment. Nat Commun. 2023;14(1):217. https:\/\/doi.org\/10.1038\/s41467-022-35615-5.","DOI":"10.1038\/s41467-022-35615-5"},{"issue":"1","key":"8602_CR51","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1038\/s41467-021-22300-2","volume":"12","author":"Q Hu","year":"2021","unstructured":"Hu Q, Hong Y, Qi P, Lu G, Mai X, Xu S, et al. Atlas of breast cancer infiltrated B-lymphocytes revealed by paired single-cell RNA-sequencing and antigen receptor profiling. Nat Commun. 2021;12(1):2186. https:\/\/doi.org\/10.1038\/s41467-021-22300-2.","journal-title":"Nat Commun"},{"issue":"18","key":"8602_CR52","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","volume":"385","author":"S Pavord","year":"2021","unstructured":"Pavord S, Scully M, Hunt BJ, Lester W, Bagot C, Craven B, et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med. 2021;385(18):1680\u201389. https:\/\/doi.org\/10.1056\/NEJMoa2109908.","journal-title":"N Engl J Med"},{"issue":"6","key":"8602_CR53","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Sautes-Fridman","year":"2019","unstructured":"Sautes-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19(6):307\u201325. https:\/\/doi.org\/10.1038\/s41568-019-0144-6.","journal-title":"Nat Rev Cancer"},{"key":"8602_CR54","doi-asserted-by":"publisher","unstructured":"Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer. Science. 2022;375(6576):eabf 9419. https:\/\/doi.org\/10.1126\/science.abf9419.","DOI":"10.1126\/science.abf9419"},{"issue":"7787","key":"8602_CR55","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-019-1836-5","volume":"576","author":"CS S","year":"2019","unstructured":"S CS, N N, A VA, Sanda MG, Carlisle JW, Bilen MA, et al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature. 2019;576(7787):465\u201370. https:\/\/doi.org\/10.1038\/s41586-019-1836-5.","journal-title":"Nature"},{"issue":"3","key":"8602_CR56","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ccell.2025.01.007","volume":"43","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Chen H, Mo H, Zhao N, Sun X, Liu B, et al. Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer. Cancer Cell. 2025;43(3):446\u201363.e7. https:\/\/doi.org\/10.1016\/j.ccell.2025.01.007.","journal-title":"Cancer Cell"},{"issue":"1","key":"8602_CR57","doi-asserted-by":"publisher","first-page":"8514","DOI":"10.1038\/s41467-024-52553-6","volume":"15","author":"W Zheng","year":"2024","unstructured":"Zheng W, Marini W, Murakami K, Sotov V, Butler M, Gorrini C, et al. Caspase-1-dependent spatiality in triple-negative breast cancer and response to immunotherapy. Nat Commun. 2024;15(1):8514. https:\/\/doi.org\/10.1038\/s41467-024-52553-6.","journal-title":"Nat Commun"},{"issue":"4","key":"8602_CR58","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.immuni.2025.03.002","volume":"58","author":"L Yu","year":"2025","unstructured":"Yu L, Liebenberg K, Shen Y, Liu F, Xu Z, Hao X, et al. Tumor-derived arachidonic acid reprograms neutrophils to promote immune suppression and therapy resistance in triple-negative breast cancer. Immunity. 2025;58(4):909\u201325.e7. https:\/\/doi.org\/10.1016\/j.immuni.2025.03.002.","journal-title":"Immunity"},{"issue":"1","key":"8602_CR59","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12967-025-06444-z","volume":"23","author":"Y Tan","year":"2025","unstructured":"Tan Y, G Y-G, Zhang X, Zhao L, Wang X, Liu W. Tumor cell-derived osteopontin promotes tumor fibrosis indirectly via tumor-associated macrophages. J Transl Med. 2025;23(1):432. https:\/\/doi.org\/10.1186\/s12967-025-06444-z.","journal-title":"J Transl Med"},{"issue":"13","key":"8602_CR60","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.7150\/ijbs.39063","volume":"15","author":"X Lu","year":"2019","unstructured":"Lu X, Yang R, Zhang L, Xi Y, Zhao J, Wang F, et al. Macrophage colony-stimulating factor mediates the recruitment of macrophages in triple negative breast cancer. Int J Biol Sci. 2019;15(13):2859\u201371. https:\/\/doi.org\/10.7150\/ijbs.39063.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"8602_CR61","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s42003-023-04525-7","volume":"6","author":"R Hirano","year":"2023","unstructured":"Hirano R, Okamoto K, Shinke M, Sato M, Watanabe S, Watanabe H, et al. Tissue-resident macrophages are major tumor-associated macrophage resources, contributing to early TNBC development, recurrence, and metastases. Commun Biol. 2023;6(1):144. https:\/\/doi.org\/10.1038\/s42003-023-04525-7.","journal-title":"Commun Biol"},{"issue":"1","key":"8602_CR62","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41698-025-00880-2","volume":"9","author":"H Jin","year":"2025","unstructured":"Jin H, Zhang D, Ma Y, Meng L, Huang S, Su H, et al. YTHDC2 manipulates anti-tumoral macrophage polarization and predicts favorable outcomes in triple negative breast cancer. Npj Precis Onc. 2025;9(1):119. https:\/\/doi.org\/10.1038\/s41698-025-00880-2.","journal-title":"Npj Precis Onc"},{"issue":"3","key":"8602_CR63","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/path.6395","volume":"265","author":"X Lu","year":"2025","unstructured":"Lu X, Gou Z, Chen H, Li L, Chen F, Bao C, et al. Extracellular matrix cancer-associated fibroblasts promote stromal fibrosis and immune exclusion in triple-negative breast cancer. The J Pathol. 2025;265(3):385\u201399. https:\/\/doi.org\/10.1002\/path.6395.","journal-title":"The J Pathol"},{"issue":"20","key":"8602_CR64","doi-asserted-by":"publisher","first-page":"5456","DOI":"10.1158\/1078-0432.CCR-20-1303","volume":"26","author":"FS Ahmed","year":"2020","unstructured":"Ahmed FS, Gaule P, McGuire J, Patel K, Blenman K, Pusztai L, et al. PD-L1 protein expression on both tumor cells and macrophages are associated with response to neoadjuvant durvalumab with chemotherapy in triple-negative breast cancer. Clin Cancer Res. 2020;26(20):5456\u201361. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1303.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"8602_CR65","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41416-025-03013-5","volume":"133","author":"M Abudula","year":"2025","unstructured":"Abudula M, Astuti Y, Raymant M, Sharma V, Schmid MC, Mielgo A. Macrophages suppress CD8 + T cell cytotoxic function in triple negative breast cancer via VISTA. Br J Cancer. 2025;133(1):40\u201351. https:\/\/doi.org\/10.1038\/s41416-025-03013-5.","journal-title":"Br J Cancer"},{"key":"8602_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-026-00895-3","volume-title":"CD52 signaling via macrophage Siglec-G represents a therapeutic target for cancer immunotherapy [J]","author":"X Qin","year":"2026","unstructured":"Qin X, Chang Y, Qiu Y, et al. CD52 signaling via macrophage Siglec-G represents a therapeutic target for cancer immunotherapy [J]. NPJ Breast Cancer; 2026."},{"issue":"1","key":"8602_CR67","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13046-018-0860-x","volume":"37","author":"J Steenbrugge","year":"2018","unstructured":"Steenbrugge J, Breyne K, Demeyere K, De Wever O, Sanders NN, Van Den Broeck W, et al. Anti-inflammatory signaling by mammary tumor cells mediates prometastatic macrophage polarization in an innovative intraductal mouse model for triple-negative breast cancer. J Exp Clin Cancer Res. 2018;37(1):191. https:\/\/doi.org\/10.1186\/s13046-018-0860-x.","journal-title":"J Exp Clin Cancer Res"},{"key":"8602_CR68","doi-asserted-by":"publisher","unstructured":"Hao M, Huang B, Wu R, Peng Z, Luo KQ. The interaction between macrophages and triple-negative breast cancer cells induces ROS-Mediated Interleukin 1\u03b1 expression to enhance Tumorigenesis and metastasis. Adv Sci. 2023;10(29):e2302857. https:\/\/doi.org\/10.1002\/advs.202302857.","DOI":"10.1002\/advs.202302857"},{"key":"8602_CR69","doi-asserted-by":"publisher","unstructured":"Tkach M, Thalmensi J, Timperi E, Gueguen P, N\u00e9vo N, Grisard E, et al. Extracellular vesicles from triple negative breast cancer promote pro-inflammatory macrophages associated with better clinical outcome. Proc Natl Acad Sci USA. 2022;119(17):e2107394119. https:\/\/doi.org\/10.1073\/pnas.2107394119.","DOI":"10.1073\/pnas.2107394119"},{"issue":"1","key":"8602_CR70","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13046-024-03050-7","volume":"43","author":"S Wang","year":"2024","unstructured":"Wang S, Li J, Hong S, Wang N, Xu S, Yang B, et al. Chemotherapy-elicited extracellular vesicle CXCL1 from dying cells promotes triple-negative breast cancer metastasis by activating TAM\/PD-L1 signaling. J Exp Clin Cancer Res. 2024;43(1):121. https:\/\/doi.org\/10.1186\/s13046-024-03050-7.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"8602_CR71","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1084\/jem.20181616","volume":"216","author":"P Tiwari","year":"2019","unstructured":"Tiwari P, Blank A, Cui C, Schoenfelt KQ, Zhou G, Xu Y, et al. Metabolically activated adipose tissue macrophages link obesity to triple-negative breast cancer. J Exp Med. 2019;216(6):1345\u201358. https:\/\/doi.org\/10.1084\/jem.20181616.","journal-title":"J Exp Med"},{"issue":"1","key":"8602_CR72","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12943-019-0988-0","volume":"18","author":"Y-S Weng","year":"2019","unstructured":"Weng Y-S, Tseng H-Y, Chen Y-A, Shen P-C, Al Haq AT, Chen L-M, et al. MCT-1\/miR-34a\/IL-6\/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer. Mol Cancer. 2019;18(1):42. https:\/\/doi.org\/10.1186\/s12943-019-0988-0.","journal-title":"Mol Cancer"},{"key":"8602_CR73","doi-asserted-by":"publisher","unstructured":"Rodriguez-Perdigon M, Jimaja S, Haeni L, Bruns N, Rothen-Rutishauser B, R\u00fcegg C. Polymersomes-mediated delivery of CSF1R inhibitor to tumor associated macrophages promotes M2 to M1-like macrophage repolarization. Macromol Biosci. 2022;22(8):e2200168. https:\/\/doi.org\/10.1002\/mabi.202200168.","DOI":"10.1002\/mabi.202200168"},{"issue":"1","key":"8602_CR74","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s10565-025-10001-1","volume":"41","author":"X Dong","year":"2025","unstructured":"Dong X, Wang X, Zheng X, Jiang H, Liu L, Ma N, et al. Targeted nanoparticle delivery system for tumor-associated macrophage reprogramming to enhance TNBC therapy. Cell Biol Toxicol. 2025;41(1):58. https:\/\/doi.org\/10.1007\/s10565-025-10001-1.","journal-title":"Cell Biol Toxicol"},{"issue":"12","key":"8602_CR75","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1158\/0008-5472.CAN-21-3714","volume":"82","author":"S Singh","year":"2022","unstructured":"Singh S, Lee N, A DA, Bado IL, Hamor C, Zhang L, et al. Chemotherapy coupled to macrophage inhibition induces T-cell and B-cell infiltration and durable regression in triple-negative breast cancer. Cancer Res. 2022;82(12):2281\u201397. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-3714.","journal-title":"Cancer Res"},{"issue":"1","key":"8602_CR76","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10549-025-07623-8","volume":"211","author":"Y-W Dai","year":"2025","unstructured":"Dai Y-W, Wu Z-X, Cheng Y, Wu H-D, Chen J-W, Lv L-X, et al. Formosanin C inhibits triple-negative breast cancer progression by suppressing the phosphorylation of STAT3 and the polarization of M2 macrophages. Breast Cancer Res Treat. 2025;211(1):71\u201389. https:\/\/doi.org\/10.1007\/s10549-025-07623-8.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"8602_CR77","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3390\/cancers15030819","volume":"15","author":"G Augimeri","year":"2023","unstructured":"Augimeri G, Fiorillo M, Morelli C, Panza S, Giordano C, Barone I, et al. The omega-3 Docosahexaenoyl Ethanolamide reduces CCL5 secretion in triple negative breast cancer cells affecting tumor progression and macrophage recruitment. Cancers (Basel). 2023;15(3):819. https:\/\/doi.org\/10.3390\/cancers15030819.","journal-title":"Cancers (Basel)"},{"key":"8602_CR78","doi-asserted-by":"publisher","unstructured":"Wang R, Zhang Y, Meng X, Zhao J, Xing Y, Ouyang Q, et al. Tumor-derived CDC37 inhibits antigen cross-presentation in dendritic cells and impairs anti-tumor immunity in breast cancer. Adv Sci. 2026;13(5):e06518. https:\/\/doi.org\/10.1002\/advs.202506518.","DOI":"10.1002\/advs.202506518"},{"issue":"1","key":"8602_CR79","doi-asserted-by":"publisher","first-page":"8592","DOI":"10.1038\/s41467-024-52577-y","volume":"15","author":"W Guo","year":"2024","unstructured":"Guo W, Tan J, Wang L, Egelston CA, Simons DL, Ochoa A, et al. Tumor draining lymph nodes connected to cold triple-negative breast cancers are characterized by Th2-associated microenvironment. Nat Commun. 2024;15(1):8592. https:\/\/doi.org\/10.1038\/s41467-024-52577-y.","journal-title":"Nat Commun"},{"key":"8602_CR80","doi-asserted-by":"publisher","unstructured":"Bassez A, Vos H, Dyck L, G, Arijs I, Desmedt C, et al. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nat Med. 2021;27(5):820\u201332. https:\/\/doi.org\/10.1038\/s41591-021-01323-8.","DOI":"10.1038\/s41591-021-01323-8"},{"key":"8602_CR81","doi-asserted-by":"publisher","unstructured":"Pilard C, Roncarati P, Ancion M, Luyckx M, Renard M, Reynders C, et al. RANKL blockade inhibits cancer growth through reversing the tolerogenic profile of tumor-infiltrating (plasmacytoid) dendritic cells. J Immunother Cancer. 2025;13(3):e010753. https:\/\/doi.org\/10.1136\/jitc-2024-010753.","DOI":"10.1136\/jitc-2024-010753"},{"issue":"6","key":"8602_CR82","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.immuni.2021.04.019","volume":"54","author":"\u00c1 de Mingo Pulido","year":"2021","unstructured":"de Mingo Pulido \u00c1, H\u00e4nggi K, Celias DP, Gardner A, Li J, Batista-Bittencourt B, et al. The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake. Immunity. 2021;54(6):1154\u201367.e7. https:\/\/doi.org\/10.1016\/j.immuni.2021.04.019.","journal-title":"Immunity"},{"issue":"1","key":"8602_CR83","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1038\/s41467-025-59356-3","volume":"16","author":"Q Zhao","year":"2025","unstructured":"Zhao Q, Pramanik J, Lu Y, Homer NZM, Imianowski CJ, Zhang B, et al. Perturbing local steroidogenesis to improve breast cancer immunity. Nat Commun. 2025;16(1):3945. https:\/\/doi.org\/10.1038\/s41467-025-59356-3.","journal-title":"Nat Commun"},{"issue":"4","key":"8602_CR84","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1158\/2326-6066.CIR-19-0449","volume":"8","author":"E Wennerberg","year":"2020","unstructured":"Wennerberg E, Spada S, Rudqvist N-P, Lhuillier C, Gruber S, Chen Q, et al. CD73 blockade promotes dendritic cell infiltration of irradiated tumors and tumor rejection. Cancer Immunol Res. 2020;8(4):465\u201378. https:\/\/doi.org\/10.1158\/2326-6066.CIR-19-0449.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"8602_CR85","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ccell.2017.11.019","volume":"33","author":"\u00c1 de Mingo Pulido","year":"2018","unstructured":"de Mingo Pulido \u00c1, A A, Hiebler S, Soliman H, Rugo HS, Krummel MF, et al. TIM-3 Regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer. Cancer Cell. 2018;33(1):60\u201374.e6. https:\/\/doi.org\/10.1016\/j.ccell.2017.11.019.","journal-title":"Cancer Cell"},{"issue":"1","key":"8602_CR86","doi-asserted-by":"publisher","first-page":"7116","DOI":"10.1038\/s41467-025-62543-x","volume":"16","author":"M Sun","year":"2025","unstructured":"Sun M, Wu Y, Chen Z, Zhang B, Liu X, Ouyang P, et al. Chimeric exosomes-derived immunomodulator restoring lymph nodes microenvironment for sensitizing TNBC immunotherapy. Nat Commun. 2025;16(1):7116. https:\/\/doi.org\/10.1038\/s41467-025-62543-x.","journal-title":"Nat Commun"},{"key":"8602_CR87","doi-asserted-by":"publisher","unstructured":"Zhou X, Wu C, Wang X, Pan N, Sun X, Chen B, et al. Tumor cell-released autophagosomes (TRAPs) induce PD-L1-decorated NETs that suppress T-cell function to promote breast cancer pulmonary metastasis. J Immunother Cancer. 2024;12(6):e009082. https:\/\/doi.org\/10.1136\/jitc-2024-009082.","DOI":"10.1136\/jitc-2024-009082"},{"issue":"3","key":"8602_CR88","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ccell.2020.12.012","volume":"39","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Cong M, Li J, He D, Wu Q, Tian P, et al. Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation. Cancer Cell. 2021;39(3):423\u201337.e7. https:\/\/doi.org\/10.1016\/j.ccell.2020.12.012.","journal-title":"Cancer Cell"},{"issue":"1","key":"8602_CR89","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/s41467-022-28438-x","volume":"13","author":"M Qi","year":"2022","unstructured":"Qi M, Xia Y, Wu Y, Zhang Z, Wang X, Lu L, et al. Lin28B-high breast cancer cells promote immune suppression in the lung pre-metastatic niche via exosomes and support cancer progression. Nat Commun. 2022;13(1):897. https:\/\/doi.org\/10.1038\/s41467-022-28438-x.","journal-title":"Nat Commun"},{"key":"8602_CR90","doi-asserted-by":"publisher","unstructured":"Zhang L, Pan J, Wang M, Yang J, Zhu S, Li L, et al. Chronic stress-induced and tumor derived SP1 + exosomes polarizing IL-1\u03b2 + neutrophils to increase lung metastasis of breast cancer. Adv Sci. 2025;12(4):e2310266. https:\/\/doi.org\/10.1002\/advs.202310266.","DOI":"10.1002\/advs.202310266"},{"issue":"1","key":"8602_CR91","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13046-025-03370-2","volume":"44","author":"S Yan","year":"2025","unstructured":"Yan S, Zhao W, Du J, Teng L, Yu T, Xu P, et al. C-FOS promotes the formation of neutrophil extracellular traps and the recruitment of neutrophils in lung metastasis of triple-negative breast cancer. J Exp Clin Cancer Res. 2025;44(1):108. https:\/\/doi.org\/10.1186\/s13046-025-03370-2.","journal-title":"J Exp Clin Cancer Res"},{"issue":"7814","key":"8602_CR92","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41586-020-2394-6","volume":"583","author":"L Yang","year":"2020","unstructured":"Yang L, Liu Q, Zhang X, Liu X, Zhou B, Chen J, et al. DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25. Nature. 2020;583(7814):133\u201338. https:\/\/doi.org\/10.1038\/s41586-020-2394-6.","journal-title":"Nature"},{"key":"8602_CR93","doi-asserted-by":"publisher","unstructured":"Park J, W RW, Amoozgar Z, Maiorino L, Fein MR, Jorns J, et al. Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps. Sci Transl Med. 2016;8(361):361ra138. https:\/\/doi.org\/10.1126\/scitranslmed.aag1711.","DOI":"10.1126\/scitranslmed.aag1711"},{"key":"8602_CR94","doi-asserted-by":"publisher","first-page":"114133","DOI":"10.1016\/j.jconrel.2025.114133","volume":"386","author":"B Hu","year":"2025","unstructured":"Hu B, Zhu D, Chan L, Tuohan M, Wang W, Lu Y, et al. Oral ruthenium-based PAD4 inhibitor modulates immunogenic cell death and neutrophil extracellular traps in triple-negative breast cancer. J Control Release. 2025;386:114133. https:\/\/doi.org\/10.1016\/j.jconrel.2025.114133.","journal-title":"J Control Release"},{"issue":"1","key":"8602_CR95","doi-asserted-by":"publisher","first-page":"101915","DOI":"10.1016\/j.xcrm.2024.101915","volume":"6","author":"Y Liu","year":"2025","unstructured":"Liu Y, Sun Q, Guo J, Yan L, Yan Y, Gong Y, et al. Dual ferroptosis induction in N2-TANs and TNBC cells via FTH1 targeting: a therapeutic strategy for triple-negative breast cancer. Cell Rep Med. 2025;6(1):101915. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101915.","journal-title":"Cell Rep Med"},{"issue":"10","key":"8602_CR96","doi-asserted-by":"publisher","first-page":"7363","DOI":"10.1021\/acsnano.3c08946","volume":"18","author":"W Zeng","year":"2024","unstructured":"Zeng W, Wang Y, Zhang Q, Hu C, Li J, Feng J, et al. Neutrophil nanodecoys inhibit tumor metastasis by blocking the interaction between tumor cells and neutrophils. ACS Nano. 2024;18(10):7363\u201378. https:\/\/doi.org\/10.1021\/acsnano.3c08946.","journal-title":"ACS Nano"},{"issue":"2","key":"8602_CR97","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1021\/acsnano.2c11764","volume":"17","author":"M Hao","year":"2023","unstructured":"Hao M, Zhu L, Hou S, Chen S, Li X, Li K, et al. Sensitizing tumors to immune checkpoint blockage via STING agonists delivered by tumor-penetrating neutrophil cytopharmaceuticals. ACS Nano. 2023;17(2):1663\u201380. https:\/\/doi.org\/10.1021\/acsnano.2c11764.","journal-title":"ACS Nano"},{"key":"8602_CR98","doi-asserted-by":"publisher","unstructured":"Yu X, Xing G, Sheng S, Jin L, Zhang Y, Zhu D, et al. Neutrophil camouflaged stealth nanovehicle for photothermal-induced tumor immunotherapy by triggering pyroptosis. Adv Sci. 2023;10(15):e2207456. https:\/\/doi.org\/10.1002\/advs.202207456.","DOI":"10.1002\/advs.202207456"},{"key":"8602_CR99","doi-asserted-by":"publisher","unstructured":"Zhao L, Huang S, Mei S, Yang Z, Xu L, Zhou N, et al. Pharmacological activation of estrogen receptor beta augments innate immunity to suppress cancer metastasis. Proc Natl Acad Sci USA. 2018;115(16):E3673\u201381. https:\/\/doi.org\/10.1073\/pnas.1803291115.","DOI":"10.1073\/pnas.1803291115"},{"issue":"1","key":"8602_CR100","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1038\/s41467-024-47068-z","volume":"15","author":"H Croizer","year":"2024","unstructured":"Croizer H, Mhaidly R, Kieffer Y, Gentric G, Djerroudi L, Leclere R, et al. Deciphering the spatial landscape and plasticity of immunosuppressive fibroblasts in breast cancer. Nat Commun. 2024;15(1):2806. https:\/\/doi.org\/10.1038\/s41467-024-47068-z.","journal-title":"Nat Commun"},{"key":"8602_CR101","doi-asserted-by":"crossref","unstructured":"Hofer I, Kieffer Y, Mencattini A, et al. An extracellular matrix-producing subset of cancer-associated fibroblasts drives chemoresistance in breast cancer via SRC activation and G0S2 upregulation [J]. Cancer Res, 2025.","DOI":"10.1158\/0008-5472.32730436"},{"issue":"7","key":"8602_CR102","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1158\/2159-8290.CD-23-0426","volume":"14","author":"J Ye","year":"2024","unstructured":"Ye J, Baer JM, Faget DV, Morikis VA, Ren Q, Melam A, et al. Senescent CAFs mediate immunosuppression and drive breast cancer progression. Cancer DiscovCancer Discov. 2024;14(7):1302\u201323. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0426.","journal-title":"Cancer DiscovCancer Discov"},{"key":"8602_CR103","doi-asserted-by":"publisher","unstructured":"Wu SZ, Roden DL, Wang C, Holliday H, Harvey K, Cazet AS, et al. Stromal cell diversity associated with immune evasion in human triple-negative breast cancer. Embo J. 2020;39(19):e104063. https:\/\/doi.org\/10.15252\/embj.2019104063.","DOI":"10.15252\/embj.2019104063"},{"issue":"7","key":"8602_CR104","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/s43018-020-0082-y","volume":"1","author":"G Friedman","year":"2020","unstructured":"Friedman G, Levi-Galibov O, David E, Bornstein C, Giladi A, Dadiani M, et al. Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4+ and PDPN+ CAFs to clinical outcome. Nat Cancer. 2020;1(7):692\u2013708. https:\/\/doi.org\/10.1038\/s43018-020-0082-y.","journal-title":"Nat Cancer"},{"issue":"1","key":"8602_CR105","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41467-023-35793-w","volume":"14","author":"JM Houthuijzen","year":"2023","unstructured":"Houthuijzen JM, R R, E VDB, Drenth AP, Wientjens E, Filipovic T, et al. CD26-negative and CD26-positive tissue-resident fibroblasts contribute to functionally distinct CAF subpopulations in breast cancer. Nat Commun. 2023;14(1):183. https:\/\/doi.org\/10.1038\/s41467-023-35793-w.","journal-title":"Nat Commun"},{"issue":"1","key":"8602_CR106","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41420-023-01768-5","volume":"10","author":"CM Lee","year":"2024","unstructured":"Lee CM, Hwang Y, Jeong JW, Kim M, Lee J, Bae SJ, et al. BRCA1 mutation promotes sprouting angiogenesis in inflammatory cancer-associated fibroblast of triple-negative breast cancer. Cell Death Discov. 2024;10(1):5. https:\/\/doi.org\/10.1038\/s41420-023-01768-5.","journal-title":"Cell Death Discov"},{"key":"8602_CR107","doi-asserted-by":"publisher","unstructured":"Liu Z, Hu S, Zhao X, Xu W, Ju F, Gu M, et al. AKAP12 positive fibroblast determines immunosuppressive contexture and immunotherapy response in patients with TNBC by promoting macrophage M2 polarization. J Immunother Cancer. 2024;12(10):e009877. https:\/\/doi.org\/10.1136\/jitc-2024-009877.","DOI":"10.1136\/jitc-2024-009877"},{"key":"8602_CR108","doi-asserted-by":"publisher","first-page":"156051","DOI":"10.1016\/j.phymed.2024.156051","volume":"135","author":"C Li","year":"2024","unstructured":"Li C, Wang X, Xing L, Chen T, Li W, Li X, et al. Huaier-induced suppression of cancer-associated fibroblasts confers immunotherapeutic sensitivity in triple-negative breast cancer. Phytomedicine. 2024;135:156051. https:\/\/doi.org\/10.1016\/j.phymed.2024.156051.","journal-title":"Phytomedicine"},{"issue":"1","key":"8602_CR109","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13046-021-01944-4","volume":"40","author":"FA Venning","year":"2021","unstructured":"Venning FA, Zornhagen KW, L L, Sj\u00f6lund J, Rodriguez-Cupello C, Kjellman P, et al. Deciphering the temporal heterogeneity of cancer-associated fibroblast subpopulations in breast cancer. J Exp Clin Cancer Res. 2021;40(1):175. https:\/\/doi.org\/10.1186\/s13046-021-01944-4.","journal-title":"J Exp Clin Cancer Res"},{"key":"8602_CR110","doi-asserted-by":"publisher","unstructured":"Maris P, Blomme A, P AP, Costanza B, Bellahc\u00e8ne A, Bianchi E, et al. Asporin is a fibroblast-derived TGF-\u03b21 inhibitor and a tumor suppressor associated with Good prognosis in breast cancer. PLoS Med. 2015;12(9):e1001871. https:\/\/doi.org\/10.1371\/journal.pmed.1001871.","DOI":"10.1371\/journal.pmed.1001871"},{"issue":"1","key":"8602_CR111","doi-asserted-by":"publisher","first-page":"8171","DOI":"10.1038\/s41467-025-63659-w","volume":"16","author":"X Wang","year":"2025","unstructured":"Wang X, Li J, Song D, Wu Y, Liu J, Yi Z, et al. AEBP1 drives fibroblast-mediated T cell dysfunction in tumors. Nat Commun. 2025;16(1):8171. https:\/\/doi.org\/10.1038\/s41467-025-63659-w.","journal-title":"Nat Commun"},{"issue":"3","key":"8602_CR112","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s10549-015-3291-9","volume":"149","author":"SY Park","year":"2015","unstructured":"Park SY, Kim HM, Koo JS. Differential expression of cancer-associated fibroblast-related proteins according to molecular subtype and stromal histology in breast cancer. Breast Cancer Res Treat. 2015;149(3):727\u201341. https:\/\/doi.org\/10.1007\/s10549-015-3291-9.","journal-title":"Breast Cancer Res Treat"},{"key":"8602_CR113","doi-asserted-by":"publisher","unstructured":"Klosowski ML, Cronise KE, Palmer EP, McAuliffe K, Stratton C, Sparks K, et al. Breast cancer cell coculture induces normal lung fibroblast transition to CAFs, promoting tumor cell dormancy and therapy resistance. Proc Natl Acad Sci USA. 2025;122(47):e2423894122. https:\/\/doi.org\/10.1073\/pnas.2423894122.","DOI":"10.1073\/pnas.2423894122"},{"issue":"1","key":"8602_CR114","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00018-025-05781-y","volume":"82","author":"G De Luca","year":"2025","unstructured":"De Luca G, Petrillo G, I I, Pane K, Cocca L, Roscigno G, et al. Fibroblasts activated by miRs-185-5p, miR-652-5p, and miR-1246 shape the tumor microenvironment in triple-negative breast cancer via PATZ1 downregulation. Cell Mol Life Sci. 2025;82(1):287. https:\/\/doi.org\/10.1007\/s00018-025-05781-y.","journal-title":"Cell Mol Life Sci"},{"key":"8602_CR115","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.omtn.2022.02.013","volume":"28","author":"I Scognamiglio","year":"2022","unstructured":"Scognamiglio I, Cocca L, Puoti I, Palma F, Ingenito F, Quintavalle C, et al. Exosomal microRNAs synergistically trigger stromal fibroblasts in breast cancer. Mol Ther - Nucleic Acids. 2022;28:17\u201331. https:\/\/doi.org\/10.1016\/j.omtn.2022.02.013.","journal-title":"Mol Ther - Nucleic Acids"},{"key":"8602_CR116","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.omto.2020.08.012","volume":"18","author":"F Su","year":"2020","unstructured":"Su F, Wang X, Pearson T, Lee J, Krishnamurthy S, Ueno NT, et al. Ablation of stromal cells with a targeted proapoptotic peptide suppresses cancer chemotherapy resistance and metastasis. Mol Ther - Oncolytics. 2020;18:579\u201386. https:\/\/doi.org\/10.1016\/j.omto.2020.08.012.","journal-title":"Mol Ther - Oncolytics"},{"issue":"21","key":"8602_CR117","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.3390\/cells14211663","volume":"14","author":"S-Y Hou","year":"2025","unstructured":"Hou S-Y, C SC, A A, Kim HR, Rosier M, Dobra K, et al. Cancer-associated fibroblasts move and interact more with triple-negative breast cancer cells and Stimulate their proliferation in a hyaluronan-dependent manner. Cells. 2025;14(21):1663. https:\/\/doi.org\/10.3390\/cells14211663.","journal-title":"Cells"},{"issue":"9","key":"8602_CR118","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.3390\/cells9092143","volume":"9","author":"G Cosentino","year":"2020","unstructured":"Cosentino G, Romero-Cordoba S, Plantamura I, Cataldo A, Iorio MV. miR-9-Mediated inhibition of EFEMP1 contributes to the acquisition of pro-tumoral Properties in normal fibroblasts. Cells. 2020;9(9):2143. https:\/\/doi.org\/10.3390\/cells9092143.","journal-title":"Cells"},{"key":"8602_CR119","doi-asserted-by":"publisher","unstructured":"He C, Peng M, Zeng X, Dong H, Sun Z, Xu J, et al. Microenvironmental G protein-coupled estrogen receptor-mediated glutamine metabolic coupling between cancer-associated fibroblasts and triple-negative breast cancer cells governs tumour progression. Clin Transl Med. 2024;14(12):e70131. https:\/\/doi.org\/10.1002\/ctm2.70131.","DOI":"10.1002\/ctm2.70131"},{"key":"8602_CR120","doi-asserted-by":"publisher","first-page":"102635","DOI":"10.1016\/j.mtbio.2025.102635","volume":"35","author":"X Xue","year":"2025","unstructured":"Xue X, Li X, Tian M, Yu L, Qian J, Bai X, et al. PH20-modified exosomes loaded curcumin inhibit desmoplastic breast cancer by breaking extracellular matrix barrier and normalizing cancer-associated fibroblasts. Mater Today Bio. 2025;35:102635. https:\/\/doi.org\/10.1016\/j.mtbio.2025.102635.","journal-title":"Mater Today Bio"},{"issue":"4","key":"8602_CR121","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.cell.2026.01.001","volume":"189","author":"S-W Zhang","year":"2026","unstructured":"Zhang S-W, Wang H, Xiao Y, Liu L-T, Shen M, Wang Z, et al. Sensory neurons drive immune exclusion by stimulating a dense extracellular matrix in the breast cancer tumor microenvironment. Cell. 2026;189(4):1039\u201355.e20. https:\/\/doi.org\/10.1016\/j.cell.2026.01.001.","journal-title":"Cell"},{"issue":"12","key":"8602_CR122","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1158\/0008-5472.CAN-19-3954","volume":"80","author":"G Vasiukov","year":"2020","unstructured":"Vasiukov G, Novitskaya T, Zijlstra A, Owens P, Ye F, Zhao Z, et al. Myeloid cell\u2013derived TGF\u03b2 signaling Regulates ECM deposition in mammary carcinoma via adenosine-dependent mechanisms. Cancer Res. 2020;80(12):2628\u201338. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-3954.","journal-title":"Cancer Res"},{"key":"8602_CR123","doi-asserted-by":"publisher","unstructured":"Sharma M, Turaga RC, Yuan Y, Satyanarayana G, Mishra F, Bian Z, et al. Simultaneously targeting cancer-associated fibroblasts and angiogenic vessel as a treatment for TNBC. J Exp Med. 2021;218(4). https:\/\/doi.org\/10.1084\/jem.20200712.","DOI":"10.1084\/jem.20200712"},{"issue":"1","key":"8602_CR124","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/onc.2016.184","volume":"36","author":"LL da Motta","year":"2017","unstructured":"da Motta LL, I I, Purshouse K, Haider S, De Bastiani MA, Baban D, et al. The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer. Oncogene. 2017;36(1):122\u201332. https:\/\/doi.org\/10.1038\/onc.2016.184.","journal-title":"Oncogene"},{"issue":"1","key":"8602_CR125","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s10456-024-09956-2","volume":"28","author":"M Moro","year":"2025","unstructured":"Moro M, Balestrero FC, Colombo G, Torretta S, Clemente N, Ciccone V, et al. Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) drives abnormal pericyte-rich vasculature in triple-negative breast cancer. Angiogenesis. 2025;28(1):4. https:\/\/doi.org\/10.1007\/s10456-024-09956-2.","journal-title":"Angiogenesis"},{"key":"8602_CR126","doi-asserted-by":"publisher","unstructured":"Diringer M-C, Coliat P, Mathieu C, Laurent N, Mura C, Banerjee M, et al. Clinically translatable transcrocetin delivery platform for correction of tumor hypoxia and enhancement of radiation therapy effects. Small. 2023;19(12):e2205961. https:\/\/doi.org\/10.1002\/smll.202205961.","DOI":"10.1002\/smll.202205961"},{"key":"8602_CR127","doi-asserted-by":"publisher","first-page":"217094","DOI":"10.1016\/j.canlet.2024.217094","volume":"598","author":"Y-X Wan","year":"2024","unstructured":"Wan Y-X, Qi X-W, Lian Y-Y, Liu Z-Y, Wang H, Qiu Y-Q, et al. Electroacupuncture facilitates vascular normalization by inhibiting Glyoxalase1 in endothelial cells to attenuate glycolysis and angiogenesis in triple-negative breast cancer. Cancer Lett. 2024;598:217094. https:\/\/doi.org\/10.1016\/j.canlet.2024.217094.","journal-title":"Cancer Lett"},{"key":"8602_CR128","doi-asserted-by":"publisher","first-page":"114423","DOI":"10.1016\/j.biopha.2023.114423","volume":"161","author":"Y Li","year":"2023","unstructured":"Li Y, Z M-Z, Zhang S-J, Sun X, Zhou C, Li J, et al. HIF-1\u03b1 inhibitor YC-1 suppresses triple-negative breast cancer growth and angiogenesis by targeting PlGF\/VEGFR1-induced macrophage polarization. Biomed Pharmacother. 2023;161:114423. https:\/\/doi.org\/10.1016\/j.biopha.2023.114423.","journal-title":"Biomed Pharmacother"},{"key":"8602_CR129","doi-asserted-by":"publisher","first-page":"114298","DOI":"10.1016\/j.bcp.2020.114298","volume":"183","author":"N Cheng","year":"2021","unstructured":"Cheng N, Bei Y, Song Y, Zhang W, Xu L, Zhang W, et al. B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy. Biochemical Pharmacol. 2021;183:114298. https:\/\/doi.org\/10.1016\/j.bcp.2020.114298.","journal-title":"Biochemical Pharmacol"},{"issue":"1","key":"8602_CR130","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13045-020-00852-y","volume":"13","author":"S Zheng","year":"2020","unstructured":"Zheng S, Yang L, Zou Y, Liang J-Y, Liu P, Gao G, et al. Long non-coding RNA HUMT hypomethylation promotes lymphangiogenesis and metastasis via activating FOXK1 transcription in triple-negative breast cancer. J Hematol Oncol. 2020;13(1):17. https:\/\/doi.org\/10.1186\/s13045-020-00852-y.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"8602_CR131","doi-asserted-by":"publisher","first-page":"4715","DOI":"10.1038\/ncomms5715","volume":"5","author":"E Lee","year":"2014","unstructured":"Lee E, Fertig EJ, Jin K, Sukumar S, Pandey NB, Popel AS. Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasis. Nat Commun. 2014;5(1):4715. https:\/\/doi.org\/10.1038\/ncomms5715.","journal-title":"Nat Commun"},{"key":"8602_CR132","doi-asserted-by":"publisher","first-page":"115533","DOI":"10.1016\/j.biopha.2023.115533","volume":"167","author":"H-Y Chen","year":"2023","unstructured":"Chen H-Y, Lin C-E, Wu S-C, Yang Z-Y, Chiang Y-F, Huang K-C, et al. Para-toluenesulfonamide, a novel potent carbonic anhydrase inhibitor, improves hypoxia-induced metastatic breast cancer cell viability and prevents resistance to \u03b1PD-1 therapy in triple-negative breast cancer. Biomed Pharmacother. 2023;167:115533. https:\/\/doi.org\/10.1016\/j.biopha.2023.115533.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"8602_CR133","doi-asserted-by":"publisher","first-page":"1760685","DOI":"10.1080\/2162402X.2020.1760685","volume":"9","author":"AC Mirando","year":"2020","unstructured":"Mirando AC, A A, I CI, Christmas BJ, Pandey NB, Stearns V, et al. Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide. Oncoimmunology. 2020;9(1):1760685. https:\/\/doi.org\/10.1080\/2162402X.2020.1760685.","journal-title":"Oncoimmunology"},{"issue":"7","key":"8602_CR134","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/j.celrep.2019.04.076","volume":"27","author":"R Evans","year":"2019","unstructured":"Evans R, Flores-Borja F, Nassiri S, Miranda E, Lawler K, Grigoriadis A, et al. Integrin-mediated macrophage adhesion promotes lymphovascular dissemination in breast cancer. Cell Rep. 2019;27(7):1967\u201378.e4. https:\/\/doi.org\/10.1016\/j.celrep.2019.04.076.","journal-title":"Cell Rep"},{"key":"8602_CR135","doi-asserted-by":"publisher","unstructured":"Kyritsi K, Pacholczyk R, Douglass E, Yu M, Fang H, Zhou G, et al. \u03b2-blocker suppresses both tumoral sympathetic neurons and perivascular macrophages during oncolytic herpes virotherapy. J Immunother Cancer. 2025;13(4):e011322. https:\/\/doi.org\/10.1136\/jitc-2024-011322.","DOI":"10.1136\/jitc-2024-011322"},{"issue":"1","key":"8602_CR136","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41523-022-00485-z","volume":"8","author":"TT Le","year":"2022","unstructured":"Le TT, Payne SL, Buckwald MN, Hayes LA, Parker SR, Burge CB, et al. Sensory nerves enhance triple-negative breast cancer invasion and metastasis via the axon guidance molecule PlexinB3. NPJ Breast Cancer. 2022;8(1):116. https:\/\/doi.org\/10.1038\/s41523-022-00485-z.","journal-title":"NPJ Breast Cancer"},{"key":"8602_CR137","doi-asserted-by":"publisher","first-page":"108113","DOI":"10.1016\/j.phrs.2026.108113","volume":"225","author":"H Makabe","year":"2026","unstructured":"Makabe H, Narita M, Nagumo Y, Fujiwara M, Hamada Y, Takise J, et al. Pain signaling via sensory neurons drives breast cancer progression through neuropeptide release and \u03ba-opioid counter-regulation. Pharmacological Res. 2026;225:108113. https:\/\/doi.org\/10.1016\/j.phrs.2026.108113.","journal-title":"Pharmacological Res"},{"key":"8602_CR138","doi-asserted-by":"publisher","unstructured":"Chang A, Botteri E, Gillis RD, L\u00f6fling L, Le CP, Ziegler AI, et al. Beta-blockade enhances anthracycline control of metastasis in triple-negative breast cancer. Sci Transl Med. 2023;15(693):eadf 1147. https:\/\/doi.org\/10.1126\/scitranslmed.adf1147.","DOI":"10.1126\/scitranslmed.adf1147"},{"issue":"1","key":"8602_CR139","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13046-022-02314-4","volume":"41","author":"S Trouvilliez","year":"2022","unstructured":"Trouvilliez S, Cicero J, Leveque R, Aubert L, Corbet C, Van Outryve A, et al. Direct interaction of TrkA\/CD44v3 is essential for NGF-promoted aggressiveness of breast cancer cells. J Exp Clin Cancer Res. 2022;41(1):110. https:\/\/doi.org\/10.1186\/s13046-022-02314-4.","journal-title":"J Exp Clin Cancer Res"},{"key":"8602_CR140","doi-asserted-by":"publisher","first-page":"116985","DOI":"10.1016\/j.biopha.2024.116985","volume":"177","author":"J Zhang","year":"2024","unstructured":"Zhang J, Teng F, Wu T, Li S, Li K. Quercetin inhibits chronic stress-mediated progression of triple-negative breast cancer by blocking \u03b22-AR\/ERK1\/2 pathway. Biomed Pharmacother. 2024;177:116985. https:\/\/doi.org\/10.1016\/j.biopha.2024.116985.","journal-title":"Biomed Pharmacother"},{"key":"8602_CR141","doi-asserted-by":"publisher","unstructured":"Lam T, Cardwell B, Liu B, Peng C, Spark M, Sursock S, et al. Hox-C12 coordinates \u03b2 2 -adrenoceptor coupling to a cAMP\/calcium feedforward loop to drive invasion in triple-negative breast cancer. Sci Signal. 2025;18(900):eadq 8279. https:\/\/doi.org\/10.1126\/scisignal.adq8279.","DOI":"10.1126\/scisignal.adq8279"},{"issue":"2","key":"8602_CR142","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/path.6423","volume":"266","author":"Y-C Kuo","year":"2025","unstructured":"Kuo Y-C, Chen C-L, L K-L, Wang H-F, Drew VJ, Lan P-C, et al. Nicotine-driven enhancement of tumor malignancy in triple-negative breast cancer via additive regulation of CHRNA9 and IGF1R. The J Pathol. 2025;266(2):230\u201345. https:\/\/doi.org\/10.1002\/path.6423.","journal-title":"The J Pathol"},{"issue":"6","key":"8602_CR143","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3390\/md22060252","volume":"22","author":"X Guo","year":"2024","unstructured":"Guo X, He L, Xu W, Wang W, Feng X, Fu Y, et al. \u03b1O-Conotoxin GeXIVA[1,2] suppresses in vivo tumor growth of triple-negative breast cancer by inhibiting AKT-mTOR, STAT3 and NF-\u03baB signaling mediated proliferation and inducing apoptosis. Mar Drugs. 2024;22(6):252. https:\/\/doi.org\/10.3390\/md22060252.","journal-title":"Mar Drugs"},{"issue":"6","key":"8602_CR144","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1172\/JCI128313","volume":"130","author":"T Gagliano","year":"2020","unstructured":"Gagliano T, Shah K, Gargani S, Lao L, Alsaleem M, Chen J, et al. PIK3C\u03b4 expression by fibroblasts promotes triple-negative breast cancer progression. J Clin Investigation. 2020;130(6):3188\u2013204. https:\/\/doi.org\/10.1172\/JCI128313.","journal-title":"J Clin Investigation"},{"issue":"9","key":"8602_CR145","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1158\/2326-6066.CIR-23-0289","volume":"12","author":"G Franzolin","year":"2024","unstructured":"Franzolin G, Brundu S, Cojocaru CF, Curatolo A, Ponzo M, Mastrantonio R, et al. PlexinB1 inactivation reprograms immune cells in the tumor microenvironment, inhibiting breast cancer growth and metastatic dissemination. Cancer Immunol Res. 2024;12(9):1286\u2013301. https:\/\/doi.org\/10.1158\/2326-6066.CIR-23-0289.","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"8602_CR146","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1038\/s41388-021-01691-y","volume":"40","author":"R Wu","year":"2021","unstructured":"Wu R, Li K, Yuan M, Luo KQ. Nerve growth factor receptor increases the tumor growth and metastatic potential of triple-negative breast cancer cells. Oncogene. 2021;40(12):2165\u201381. https:\/\/doi.org\/10.1038\/s41388-021-01691-y.","journal-title":"Oncogene"},{"issue":"1","key":"8602_CR147","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1158\/2326-6066.CIR-23-0076","volume":"12","author":"B Donati","year":"2024","unstructured":"Donati B, Reggiani F, Torricelli F, Santandrea G, Rossi T, Bisagni A, et al. Spatial distribution of immune cells drives resistance to neoadjuvant chemotherapy in triple-negative breast cancer. Cancer Immunol Res. 2024;12(1):120\u201334. https:\/\/doi.org\/10.1158\/2326-6066.CIR-23-0076.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"8602_CR148","doi-asserted-by":"publisher","first-page":"100652","DOI":"10.1016\/j.modpat.2024.100652","volume":"38","author":"H Mi","year":"2025","unstructured":"Mi H, Varadhan R, M AM, Emens LA, Santa-Maria CA, Popel AS. Spatial architecture of single-cell and vasculature in tumor microenvironment predicts clinical outcomes in triple-negative breast cancer. Mod Pathol. 2025;38(2):100652. https:\/\/doi.org\/10.1016\/j.modpat.2024.100652.","journal-title":"Mod Pathol"},{"issue":"19","key":"8602_CR149","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.1158\/1078-0432.CCR-21-0144","volume":"27","author":"C Yam","year":"2021","unstructured":"Yam C, Y E-Y, Chang JT, Bassett RL, Alatrash G, Garber H, et al. Immune phenotype and response to neoadjuvant therapy in triple-negative breast cancer. Clin Cancer Res. 2021;27(19):5365\u201375. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0144.","journal-title":"Clin Cancer Res"},{"key":"8602_CR150","doi-asserted-by":"publisher","first-page":"113535","DOI":"10.1016\/j.ejca.2024.113535","volume":"200","author":"S Rusakiewicz","year":"2024","unstructured":"Rusakiewicz S, Tyekucheva S, Tissot-Renaud S, Chaba K, Imbimbo M, Benedetti F, et al. Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: analysis from the international breast cancer study group (IBCSG) trial 22\u201300. Eur J Cancer. 2024;200:113535. https:\/\/doi.org\/10.1016\/j.ejca.2024.113535.","journal-title":"Eur J Cancer"},{"issue":"1","key":"8602_CR151","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41523-021-00291-z","volume":"7","author":"JC Wortman","year":"2021","unstructured":"Wortman JC, He T-F, S S, Zhang RZ, Rosario A, Wang R, et al. Spatial distribution of B cells and lymphocyte clusters as a predictor of triple-negative breast cancer outcome. NPJ Breast Cancer. 2021;7(1):84. https:\/\/doi.org\/10.1038\/s41523-021-00291-z.","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"8602_CR152","doi-asserted-by":"publisher","first-page":"6796","DOI":"10.1038\/s41467-023-42504-y","volume":"14","author":"S Zhao","year":"2023","unstructured":"Zhao S, Chen D-P, Fu T, Yang J-C, Ma D, Zhu X-Z, et al. Single-cell morphological and topological atlas reveals the ecosystem diversity of human breast cancer. Nat Commun. 2023;14(1):6796. https:\/\/doi.org\/10.1038\/s41467-023-42504-y.","journal-title":"Nat Commun"},{"issue":"4","key":"8602_CR153","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/s44321-024-00050-0","volume":"16","author":"M Inayatullah","year":"2024","unstructured":"Inayatullah M, Mahesh A, Turnbull AK, Dixon JM, Natrajan R, Tiwari VK. Basal\u2013epithelial subpopulations underlie and predict chemotherapy resistance in triple-negative breast cancer. EMBO Mol Med. 2024;16(4):823\u201353. https:\/\/doi.org\/10.1038\/s44321-024-00050-0.","journal-title":"EMBO Mol Med"},{"key":"8602_CR154","doi-asserted-by":"publisher","first-page":"1137561","DOI":"10.3389\/fimmu.2023.1137561","volume":"14","author":"X Ren","year":"2023","unstructured":"Ren X, Song Y, Pang J, Chen L, Zhou L, Liang Z, et al. Prognostic value of various immune cells and immunoscore in triple-negative breast cancer. Front Immunol. 2023;14:1137561. https:\/\/doi.org\/10.3389\/fimmu.2023.1137561.","journal-title":"Front Immunol"},{"issue":"10","key":"8602_CR155","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1016\/j.cell.2022.03.033","volume":"185","author":"P Baldominos","year":"2022","unstructured":"Baldominos P, Barbera-Mourelle A, Barreiro O, Huang Y, Wight A, Cho J-W, et al. Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche. Cell. 2022;185(10):1694\u2013708.e19. https:\/\/doi.org\/10.1016\/j.cell.2022.03.033.","journal-title":"Cell"},{"issue":"1","key":"8602_CR156","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1038\/s41467-021-25962-0","volume":"12","author":"D Hammerl","year":"2021","unstructured":"Hammerl D, M JWM, Timmermans M, Smid M, Trapman-Jansen AM, Foekens R, et al. Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. Nat Commun. 2021;12(1):5668. https:\/\/doi.org\/10.1038\/s41467-021-25962-0.","journal-title":"Nat Commun"},{"issue":"1","key":"8602_CR157","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1038\/s41467-018-05220-6","volume":"9","author":"AS Cazet","year":"2018","unstructured":"Cazet AS, Hui MN, L BL, Wu SZ, Roden D, Chan C-L, et al. Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. Nat Commun. 2018;9(1):2897. https:\/\/doi.org\/10.1038\/s41467-018-05220-6.","journal-title":"Nat Commun"},{"issue":"1","key":"8602_CR158","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13058-018-1014-y","volume":"20","author":"JR Diamond","year":"2018","unstructured":"Diamond JR, Eckhardt SG, Pitts TM, van Bokhoven A, Aisner D, Gustafson DL, et al. A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer. Breast Cancer Res. 2018;20(1):82. https:\/\/doi.org\/10.1186\/s13058-018-1014-y.","journal-title":"Breast Cancer Res"},{"key":"8602_CR159","doi-asserted-by":"publisher","unstructured":"Liu J, Liu Q, Li Y, Li Q, Su F, Yao H, et al. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial. J Immunother Cancer. 2020;8(1):e000696. https:\/\/doi.org\/10.1136\/jitc-2020-000696.","DOI":"10.1136\/jitc-2020-000696"},{"issue":"1","key":"8602_CR160","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1038\/s41467-022-30569-0","volume":"13","author":"J Liu","year":"2022","unstructured":"Liu J, Wang Y, Tian Z, Lin Y, Li H, Zhu Z, et al. Multicenter phase II trial of Camrelizumab combined with apatinib and eribulin in heavily pretreated patients with advanced triple-negative breast cancer. Nat Commun. 2022;13(1):3011. https:\/\/doi.org\/10.1038\/s41467-022-30569-0.","journal-title":"Nat Commun"},{"key":"8602_CR161","doi-asserted-by":"publisher","unstructured":"Chen M, Huang R, Rong Q, Yang W, Shen X, Sun Q, et al. Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial. J Immunother Cancer. 2025;13(4):e011314. https:\/\/doi.org\/10.1136\/jitc-2024-011314.","DOI":"10.1136\/jitc-2024-011314"},{"issue":"1","key":"8602_CR162","doi-asserted-by":"publisher","first-page":"7018","DOI":"10.1038\/s41467-023-42744-y","volume":"14","author":"L Buisseret","year":"2023","unstructured":"Buisseret L, Loirat D, Aftimos P, Maurer C, Punie K, Debien V, et al. Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I\/II trial. Nat Commun. 2023;14(1):7018. https:\/\/doi.org\/10.1038\/s41467-023-42744-y.","journal-title":"Nat Commun"},{"issue":"7","key":"8602_CR163","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1038\/s41591-025-03776-7","volume":"31","author":"S-Y Wu","year":"2025","unstructured":"Wu S-Y, Jin X, Liu Y, Wang Z-Y, Zuo W-J, Ma D, et al. Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial. Nat Med. 2025;31(7):2405\u201315. https:\/\/doi.org\/10.1038\/s41591-025-03776-7.","journal-title":"Nat Med"},{"issue":"8","key":"8602_CR164","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","volume":"30","author":"S Loibl","year":"2019","unstructured":"Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer J-U, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019;30(8):1279\u201388. https:\/\/doi.org\/10.1093\/annonc\/mdz158.","journal-title":"Ann Oncol"},{"issue":"6","key":"8602_CR165","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","volume":"25","author":"L Voorwerk","year":"2019","unstructured":"Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019;25(6):920\u201328. https:\/\/doi.org\/10.1038\/s41591-019-0432-4.","journal-title":"Nat Med"},{"issue":"3","key":"8602_CR166","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S1470-2045(24)00757-5","volume":"26","author":"N Zdenkowski","year":"2025","unstructured":"Zdenkowski N, Kuper-Hommel MJJ, Niman SM, Francis PA, Baron-Hay S, Fox W, et al. Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902\/IBCSG 61\u201320; Neo-N): a non-comparative, open-label, randomised, phase 2 trial. The Lancet Oncol. 2025;26(3):367\u201377. https:\/\/doi.org\/10.1016\/S1470-2045(24)00757-5.","journal-title":"The Lancet Oncol"},{"issue":"1","key":"8602_CR167","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","volume":"21","author":"P Schmid","year":"2020","unstructured":"Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncol. 2020;21(1):44\u201359. https:\/\/doi.org\/10.1016\/S1470-2045(19)30689-8.","journal-title":"The Lancet Oncol"},{"issue":"10265","key":"8602_CR168","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S-A, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(20)32531-9.","journal-title":"Lancet"},{"issue":"9","key":"8602_CR169","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1910549.","journal-title":"N Engl J Med"},{"issue":"6","key":"8602_CR170","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2112651","volume":"386","author":"P Schmid","year":"2022","unstructured":"Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, K\u00fcmmel S, et al. Event-free survival with Pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386(6):556\u201367. https:\/\/doi.org\/10.1056\/NEJMoa2112651.","journal-title":"N Engl J Med"},{"issue":"5","key":"8602_CR171","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.annonc.2024.02.002","volume":"35","author":"L Pusztai","year":"2024","unstructured":"Pusztai L, Denkert C, O\u2019SHAUGHNESSY J, Cortes J, Dent R, McArthur H, et al. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522. Ann Oncol. 2024;35(5):429\u201336. https:\/\/doi.org\/10.1016\/j.annonc.2024.02.002.","journal-title":"Ann Oncol"},{"issue":"4","key":"8602_CR172","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","volume":"22","author":"EP Winer","year":"2021","unstructured":"Winer EP, Lipatov O, Im SA, Goncalves A, Mu\u00f1oz-Couselo E, Lee KS, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. The Lancet Oncol. 2021;22(4):499\u2013511. https:\/\/doi.org\/10.1016\/S1470-2045(20)30754-3.","journal-title":"The Lancet Oncol"},{"issue":"8","key":"8602_CR173","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","volume":"32","author":"D Miles","year":"2021","unstructured":"Miles D, Gligorov J, Andre F, Cameron D, Schneeweiss A, Barrios C, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer. Ann Oncol. 2021;32(8):994\u20131004. https:\/\/doi.org\/10.1016\/j.annonc.2021.05.801.","journal-title":"Ann Oncol"},{"issue":"2","key":"8602_CR174","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1001\/jamaoncol.2023.5033","volume":"10","author":"P Sharma","year":"2024","unstructured":"Sharma P, Stecklein SR, Yoder R, Staley JM, Schwensen K, O\u2019Dea A, et al. Clinical and biomarker findings of neoadjuvant Pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT phase 2 clinical trial. JAMA Oncol. 2024;10(2):227\u201335. https:\/\/doi.org\/10.1001\/jamaoncol.2023.5033.","journal-title":"JAMA Oncol"},{"issue":"1","key":"8602_CR175","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13073-024-01388-3","volume":"16","author":"X Zhang","year":"2024","unstructured":"Zhang X, Goedegebuure SP, Chen MY, Mishra R, Zhang F, Yu YY, et al. Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients. Genome Med. 2024;16(1):131. https:\/\/doi.org\/10.1186\/s13073-024-01388-3.","journal-title":"Genome Med"},{"issue":"1","key":"8602_CR176","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41523-022-00486-y","volume":"8","author":"Y Abdou","year":"2022","unstructured":"Abdou Y, Goudarzi A, Yu JX, Upadhaya S, Vincent B, Carey LA. Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors. NPJ Breast Cancer. 2022;8(1):121. https:\/\/doi.org\/10.1038\/s41523-022-00486-y.","journal-title":"NPJ Breast Cancer"},{"issue":"14","key":"8602_CR177","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1158\/0008-5472.CAN-23-3429","volume":"84","author":"J Xia","year":"2024","unstructured":"Xia J, Zhang L, Peng X, Tu J, Li S, He X, et al. IL1R2 blockade alleviates immunosuppression and potentiates anti-PD-1 efficacy in triple-negative breast cancer. Cancer Res. 2024;84(14):2282\u201396. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-3429.","journal-title":"Cancer Res"},{"key":"8602_CR178","doi-asserted-by":"publisher","unstructured":"Esteva FJ, Hubbard-Lucey VM, Tang J, Pusztai L. Immunotherapy and targeted therapy combinations in metastatic breast cancer. The Lancet Oncol. 2019;20(3):e175\u201386. https:\/\/doi.org\/10.1016\/S1470-2045(19)30026-9.","DOI":"10.1016\/S1470-2045(19)30026-9"},{"issue":"21","key":"8602_CR179","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","volume":"34","author":"R Nanda","year":"2016","unstructured":"Nanda R, Chow LQM, Dees EC, Berger R, Gupta S, Geva R, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase ib KEYNOTE-012 study. JCO. 2016;34(21):2460\u201367. https:\/\/doi.org\/10.1200\/JCO.2015.64.8931.","journal-title":"JCO"},{"issue":"3","key":"8602_CR180","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdy517","volume":"30","author":"S Adams","year":"2019","unstructured":"Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort a of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30(3):397\u2013404. https:\/\/doi.org\/10.1093\/annonc\/mdy517.","journal-title":"Ann Oncol"},{"issue":"1","key":"8602_CR181","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s40425-019-0680-3","volume":"7","author":"AS Zimmer","year":"2019","unstructured":"Zimmer AS, Nichols E, A A, Peer C, Cao L, Lee M-J, et al. A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1\u20133 inhibitor, cediranib, in recurrent women\u2019s cancers with biomarker analyses. J Immunother Cancer. 2019;7(1):197. https:\/\/doi.org\/10.1186\/s40425-019-0680-3.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"8602_CR182","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jamaoncol.2020.7310","volume":"7","author":"OM Filho","year":"2021","unstructured":"Filho OM, Stover DG, Asad S, Ansell PJ, Watson M, Loibl S, et al. Association of Immunophenotype with pathologic complete response to neoadjuvant chemotherapy for triple-negative breast cancer: a secondary analysis of the BrighTNess phase 3 randomized clinical trial. JAMA Oncol. 2021;7(4):603\u201308. https:\/\/doi.org\/10.1001\/jamaoncol.2020.7310.","journal-title":"JAMA Oncol"},{"issue":"21","key":"8602_CR183","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1158\/0008-5472.CAN-24-5023","volume":"85","author":"AL Rinkenbaugh","year":"2025","unstructured":"Rinkenbaugh AL, Qi Y, Cai S, Shao J, Baameur Hancock F, Jeter-Jones SL, et al. An annotated biobank of triple-negative breast cancer patient-derived xenografts features treatment-na\u00efve and longitudinal samples during neoadjuvant chemotherapy. Cancer Res. 2025;85(21):4062\u201380. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-5023.","journal-title":"Cancer Res"},{"issue":"2","key":"8602_CR184","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41422-020-0375-9","volume":"31","author":"YZ Jiang","year":"2021","unstructured":"Jiang YZ, Liu Y, Xiao Y, Hu X, Jiang L, Zuo W-J, et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Cell Res. 2021;31(2):178\u201386. https:\/\/doi.org\/10.1038\/s41422-020-0375-9.","journal-title":"Cell Res"},{"issue":"11","key":"8602_CR185","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1038\/s41591-024-03249-3","volume":"30","author":"I Nederlof","year":"2024","unstructured":"Nederlof I, Isaeva OI, De Graaf M, Gielen RCAM, Bakker NAM, Rolfes AL, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial. Nat Med. 2024;30(11):3223\u201335. https:\/\/doi.org\/10.1038\/s41591-024-03249-3.","journal-title":"Nat Med"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08602-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08602-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08602-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:01:33Z","timestamp":1791417693000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08602-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":185,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8602"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08602-3","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"14 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No potential conflict of interest was reported by the authors.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1263"}}